Want to see HRMY full AI Analyst Report?
Harmony Biosciences Holdings (HRMY) Financial Statements
Harmony Biosciences Holdings Financial Overview
Harmony Biosciences Holdings's market cap is currently $2.26B. The company's EPS TTM is $3.13; its P/E ratio is 12.38; Harmony Biosciences Holdings is scheduled to report earnings on November 4, 2026, and the estimated EPS forecast is $1.09. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 868.45M | $ 714.73M | $ 582.02M | $ 437.86M | $ 305.44M |
| Gross Profit | $ 670.11M | $ 557.92M | $ 460.79M | $ 354.37M | $ 249.92M |
| Operating Income | $ 208.47M | $ 190.83M | $ 192.03M | $ 120.19M | $ 87.53M |
| EBITDA | $ 255.05M | $ 233.41M | $ 221.51M | $ 146.87M | $ 80.46M |
| Net Income | $ 158.69M | $ 145.49M | $ 128.85M | $ 181.47M | $ 34.60M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 775.34M | $ 467.19M | $ 353.46M | $ 323.12M | $ 234.31M |
| Total Assets | $ 1.27B | $ 999.20M | $ 811.45M | $ 673.87M | $ 433.44M |
| Total Debt | $ 239.58M | $ 181.41M | $ 193.57M | $ 191.65M | $ 195.74M |
| Net Debt | $ -512.92M | $ -271.60M | $ -118.09M | $ -52.14M | $ -38.56M |
| Total Liabilities | $ 401.41M | $ 340.05M | $ 344.46M | $ 271.03M | $ 246.94M |
| Stockholders' Equity | $ 870.22M | $ 659.15M | $ 466.99M | $ 402.84M | $ 186.51M |
| Cash Flow | |||||
| Free Cash Flow | $ 347.89M | $ 218.67M | $ 219.07M | $ 144.29M | $ 98.26M |
| Operating Cash Flow | $ 348.20M | $ 219.82M | $ 219.39M | $ 144.47M | $ 98.56M |
| Investing Cash Flow | $ -39.65M | $ -67.48M | $ -46.44M | $ -141.83M | $ -100.30M |
| Financing Cash Flow | $ -9.05M | $ -11.00M | $ -105.55M | $ 6.84M | $ 7.42M |
Currency in USD